<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05120973</url>
  </required_header>
  <id_info>
    <org_study_id>N21SPL</org_study_id>
    <nct_id>NCT05120973</nct_id>
  </id_info>
  <brief_title>Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.</brief_title>
  <acronym>SPLIT</acronym>
  <official_title>MultiSPectral fLuorescence Imaging as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies During Lymph Node Dissections in Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multispectral imaging of the lymphatic draining pattern of the tumor and the abdominall&#xD;
      wall/lower limb to evaluate technical feasibility to differentiate these patterns and in the&#xD;
      future reduce the amount of complications that result from damage to lymphatic structures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By preventing unnecessary resection of healthy lymphatic tissue during extended lymph node&#xD;
      dissections, we will be able to reduce the degree and amount of complications that result&#xD;
      from damage to the lymphatic structures. We aim to evaluate the technical feasibility of&#xD;
      imaging two different lymphatic drainage profiles, namely that of healthy tissue (i.e. the&#xD;
      lower limbs/abdominal wall) and that of the primary tumour (i.e. prostate). To realize the&#xD;
      differentiation, real-time multispectral fluorescence imaging of two spectrally different&#xD;
      tracers (the lymphangiographic tracer fluorescein (injected in the lower limbs and abdominal&#xD;
      wall) and sentinel node (SN) specific tracer Indocyanine Green (ICG)-99mTc-nanocolloid&#xD;
      (injected in the tumour, followed by ac control lymphoscintigraphy and SPECT/CT)) will allow&#xD;
      for multispectral (or multicolor) fluorescence. Complementary to the routine surgical&#xD;
      procedure, e.g. radical prostatectomy with extended pelvic lymph node dissection (ePLND), the&#xD;
      lymphatic drainage pattern of both the tumour and of healthy tissue, i.e. lower limbs and&#xD;
      abdominal wall, will be determined in the surgical field/surgical specimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of this intraoperative visualisation technique</measure>
    <time_frame>During surgery</time_frame>
    <description>The ability to visually differentiate the draining lymphatics of the lower limbs and abdominal wall, (LNLower limb/abdominal wall; fluorescein) from the disease associated LNs (LNprostate cancer; ICG-99mTc-nanocolloid) during lymph node dissection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic localisation</measure>
    <time_frame>During surgery</time_frame>
    <description>Determine the anatomical relationship between lymphatic tumour spread and the lymphatic drainage profiles of the lower limbs and primary tumour (i.e. prostate) in relation to ePLND template.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multispectral imaging</intervention_name>
    <description>Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men &gt;18 yrs with primary diagnosed prostate cancer eligible for robot assisted radical&#xD;
        prostatectomy and lymph node dissection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, aged â‰¥ 18 years.&#xD;
&#xD;
          -  WHO performance status 0,1, or 2.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Histopathologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Increased risk of nodal metastases according to the MSKCC nomogram (&gt; 7%)&#xD;
&#xD;
          -  Scheduled for surgical (laparoscopic) prostatectomy including ePLND-&#xD;
&#xD;
          -  Suitable for RP and ePLND, as per institutional guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate cancer patients with prior abdominal or inguinal surgery&#xD;
&#xD;
          -  History of allergy to iodine, food or medicinal induced urticaria, asthma, eczema, or&#xD;
             aller-gic rhinitis&#xD;
&#xD;
          -  Hyperthyroid or thyroidal adenoma&#xD;
&#xD;
          -  Kidney insufficiency&#xD;
&#xD;
          -  History of oversensitivity to FLUORESCITE composites&#xD;
&#xD;
          -  Patients using beta-blockers&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>men with prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henk van der Poel, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henk van der Poel, Prof. MD</last_name>
    <phone>0205129111</phone>
    <email>h.vd.poel@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fijs van Leeuwen, Prof</last_name>
    <phone>0205129111</phone>
    <email>f.w.b.van_leeuwen@lumc.nl</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

